Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.

The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.

Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.

Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.